UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549 

 

FORM 8-K

 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 19, 2024

 

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

  

Nevada

 

000-53500

 

87-0622284

(State or other jurisdiction

 

(Commission File Number)

 

(I.R.S. Employer

of incorporation)

 

 

 

Identification Number)

 

211 E Osborn Road, Phoenix, AZ 85012

(Address of principal executive offices)

 

(480) 399-2822

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

CELZ

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

Item 5.07  Submission of Matters to a Vote of Security Holders.

 

On July 19, 2024, Creative Medical Technology Holdings, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) to consider and vote on proposals for (i) the election of the director nominees named in the definitive proxy statement (the “Proxy Statement”) for the Annual Meeting filed with the Securities and Exchange Commission on June 5, 2024 (“Proposal I”); (ii) the approval of the compensation of the Company’s named executive officers (“Proposal II”); and (iii) the ratification of the appointment of Haynie & Company to serve as the Company’s independent registered public accountants (“Proposal III”).  Each of the foregoing proposals is described in more detail in the Proxy Statement.  Stockholders holding an aggregate of 832,170 shares of common stock, representing 61.7% of the outstanding shares of the Company’s common stock as of the record date, and which constituted a quorum, were present in person or represented by proxy at the Annual Meeting.   The proposal described in the Proxy Statement to increase the authorized shares of common stock of the Company was withdrawn by management prior to the Annual Meeting and was not voted on.  The results of the voting at the Annual Meeting are presented below.

 

Proposal I - The five director nominees were all elected to the Board as follows:

 

Director

 

For

 

 

Withhold

 

Timothy Warbington

 

 

312,403

 

 

 

147,859

 

Donald Dickerson

 

 

338,694

 

 

 

121,568

 

Michael H. Finger

 

 

337,737

 

 

 

122,525

 

Susan Snow

 

 

311,531

 

 

 

148,731

 

Bruce S. Urdang, Esq.

 

 

337,685

 

 

 

122,577

 

 

Proposal II - The compensation of the Company’s named executive officers was approved as follows:

 

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

 

217,019

 

 

 

227,926

 

 

 

15,317

 

 

 

371,908

 

 

Proposal III –The ratification of the appointment of Haynie & Company was approved as follows:

 

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

 

684,717

 

 

 

90,973

 

 

 

56,480

 

 

 

N/A

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d)

 

Exhibits.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Creative Medical Technology Holdings, Inc.

 

 

 

 

Date: July 25, 2024

By:

/s/ Timothy Warbington

 

 

 

Timothy Warbington, Chief Executive Officer

 

 

 
3

 

v3.24.2
Cover
Jul. 19, 2024
Cover [Abstract]  
Entity Registrant Name CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Entity Central Index Key 0001187953
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Jul. 19, 2024
Entity File Number 000-53500
Entity Incorporation State Country Code NV
Entity Tax Identification Number 87-0622284
Entity Address Address Line 1 211 E Osborn Road
Entity Address City Or Town Phoenix
Entity Address State Or Province AZ
Entity Address Postal Zip Code 85012
City Area Code 480
Local Phone Number 399-2822
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol CELZ
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Creative Medical Technol... (NASDAQ:CELZ)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Creative Medical Technol... Charts.
Creative Medical Technol... (NASDAQ:CELZ)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Creative Medical Technol... Charts.